Pinned Tweet
$HIMS is the comeback story of 2026!
True
$AMD
4
202
Bought more $HIMS today
Retail capitulation
R/r better than ever
16-hour flight.
In-flight entertainment has @hubermanlab loaded.
Queued up “How to Defeat Jet Lag, Shift Work & Sleeplessness” first.
@hubermanlab — any extra tips for long-haul that aren’t in the episode? Trying not to arrive destroyed.
$HIMS 🤝
1
207
I ain't gonna lie
$HIMS earnings are shit
We are ok long-term (i still believe in the long-term thesis)
Huberman holding the stock up from hitting the teens
2
329
Just added to my $HIMS position
<$25 is an easy add for me
1
5
602
I couldn't agree more
$HIMS
Every great and unfortunate business is heavy green today, except $NVDA and $HIMS, which are getting absolutely demolished.
My best guess for this striking $HIMS decline ahead of earnings is pessimism around margins and next quarter’s guidance.
I also wouldn’t underestimate how many hedge funds could have been absolutely wrecked over the past few weeks and now need to count every penny to pay their bills.
A fund manager can believe $HIMS will be worth three times as much in two or three years and still sell today because they’re worried about the next quarter. Or perhaps they’re simply worried that other equally wrecked funds will find something to worry about and sell first.
Wrecked stuff.
What makes $HIMS particularly interesting is that its long thesis and short-term earnings expectations seem be diverging considerably now.
Peptides, international expansion, and the new Lilly partnership are all incredibly bullish signals for the future that significantly strengthen the case for Hims as a healthcare distribution platform. Meanwhile, the market seems to be obsessing over near-term margins and guidance.
Which is unreal, really. Imagine committing your capital to a small-cap company trying to build everything at once, then judging the entire effort by its near-term margins or next quarter’s guidance – all during its buildout year, and then chickening out on earnings day. An extraordinary shortage of foresight, market IQ, imagination, and balance sheet strength, but nothing new under the sun.
In any case, frankly, I couldn’t care less what these unfortunate market participants think about the stock.
I’ll tune in to the earnings call for updates on the healthcare network, Lilly and Novo, peptides, biomarkers, data and AI, and personalization. These are the things that will ultimately make or break my investment thesis.
When I first invested in $HIMS, I never signed up for this quarter anyway. I signed up for the long term, and for the possibility of making world-class healthcare, currently a privilege of the wealthy few, affordable and accessible to everyone.
That’s the business I invested in. And that’s what I’ll be watching. For me, this year is about the vision and the foundations. Next year, the focus shifts more toward the financials.
13
8,586
$HIMS
Shorts are at it again
They'll regret playing this game
4
272
Stay invested
In the right companies
$SPY
1
61
$HIMS 👀
As a pharmacy owner, $HIMS could put me out of business whenever it wants.
Here’s why I’m bullish on the stock.
Getting testosterone cypionate through my pharmacy:
Doctor’s consultation: £300
Blood tests: £350
Testosterone cypionate (3-month supply): £233
Total: £883 (~$1,185) for 3 months
Getting it through $HIMS:
$79/month = $237 for 3 months.
Same treatment. A fraction of the cost.
This is what disrupting healthcare looks like.
3
221
People deserve to have access to the most innovative treatments. That’s why we work with leaders across the industry, and starting today, that includes @EliLillyandCo.
When innovators work together, it’s better for everyone. Customers can access more personal care, providers have a well-rounded picture of how their patients are doing, and drugmakers can be confident that the people who need their medications the most will be able to get their hands on it and stick to it.
Lilly is one of the most innovative companies in the world, and we share a commitment to reaching real people with real impact. Working together means we can combine some of the world’s best medicines with our powerful platform to help more people feel great.
Read more, including important info: news.hims.com/newsroom/lilly…
1
126























